A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers
In a real-world propensity-score matched analysis, no survival difference was noted with the combination of FOLFIRI-Ram compared with Ram-Pac; however, FOLFIRI-Ram was associated with a significantly longer rwTTD. Altogether, these data suggest FOLFIRI-Ram is a potential alternative for second line treatment of UGI cancers.
Authors
- Nilesh Verma
- Nina Niu Sanford (ORCID: https://orcid.org/0000-0001-7840-5700)
- Timothy J. Brown (ORCID: https://orcid.org/0000-0002-4843-4639)
- Matthew R. Porembka (ORCID: https://orcid.org/0000-0003-1596-0058)
- Jonathan Hyak
- Sam C. Wang (ORCID: https://orcid.org/0000-0003-3626-5273)
- Deepak Vadehra (ORCID: https://orcid.org/0000-0002-1901-8222)
- Udhayvir Singh Grewal (ORCID: https://orcid.org/0000-0002-9638-3629)
- Victoria Chung (ORCID: https://orcid.org/0000-0003-0034-3348)
- Shahed N. Badiyan (ORCID: https://orcid.org/0000-0001-6243-526X)
- Peifeng Ruan (ORCID: https://orcid.org/0000-0002-1364-7992)
- Syed Mohammad Ali Kazmi (ORCID: https://orcid.org/0000-0002-3367-367X)
- Nicholas J. Hornstein (ORCID: https://orcid.org/0000-0003-2089-8236)
- Amy Little Jones (ORCID: https://orcid.org/0000-0002-2885-0969)
Institutions
- Roswell Park Comprehensive Cancer Center (US)
- Emory University (US)
- Harold C. Simmons Comprehensive Cancer Center
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- American Journal of Clinical Oncology
- Published
- 2025-12-08
- DOI
- https://doi.org/10.1097/coc.0000000000001283
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00